Lucid Diagnostics (LUCD) Stock Price, News & Analysis

Company Overview

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer.

The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.

Lucid was formed as a subsidiary of PAVmed and became an independent publicly traded company in 2021. The company is based in the United States and is led by co-founder and Chief Executive Officer Lishan Aklog, M.D.

Key Stats

• Today's Range: $0.38 to $0.43
• 50-Day Range: $0.33 to $0.95
• 52-Week Range: $0.30 to $1.63
• Volume: 2.36 million shs
• Average Volume: 13.05 million shs
• Market Capitalization: $84.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.19
• Consensus Rating: Moderate Buy

Lucid Diagnostics Stock Analysis - MarketRank™

Lucid Diagnostics scored higher than 54% of companies evaluated by MarketBeat, and ranked 446th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lucid Diagnostics has a consensus price target of $4.19, representing about 905.9% upside from its current price of $0.42.

Amount of Analyst Coverage

Lucid Diagnostics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.29) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lucid Diagnostics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lucid Diagnostics is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.92% of the float of Lucid Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Lucid Diagnostics has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lucid Diagnostics has recently increased by 9.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lucid Diagnostics does not currently pay a dividend.

Dividend Growth

Lucid Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.08

News Sentiment

Lucid Diagnostics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

3 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of Lucid Diagnostics is held by insiders.

Percentage Held by Institutions

74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LUCD
• CIK: 1799011
• Web: www.luciddx.com
• Phone: 212-949-4319
• Fax: N/A
• Employees: 82
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Lucid Diagnostics: $4.19
• High Price Target: $9.25
• Low Price Target: $2.00
• Potential Upside/Downside: +905.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.01 million
• Net Margins: -959.76%
• Pretax Margin: -959.76%
• Return on Equity: N/A
• Return on Assets: -119.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 1.31

Sales & Book Value

• Annual Sales: $4.71 million
• Price / Sales: 17.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.31) per share
• Price / Book: -1.34

Miscellaneous

• Outstanding Shares: 203,240,000
• Free Float: 189,220,000
• Market Cap: $84.61 million
• Optionable: No Data
• Beta: 1.19